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167 Inhalation with PARI eFlow® rapid reduces treatment burden
signiﬁcantly in adult CF patients without altering lung function
R. Fischer, S. Naehrig, M. Kerscher, R.M. Huber. Pneumology, Med. Klinik, University
of Munich, Munich, Bavaria, Germany
The time required for daily inhalation therapy puts treatment adherence at risk in CF
patients. The new nebuliser PARI eFlow® rapid with a microperforated oscillating
membrane allows a highly efﬁcient aerosol delivery and reduces inhalation time.
However, lung function might be impaired when inhalation time is reduced.
We therefore compared lung function, inhalation time and treatment satisfaction in 70
adult CF patients 12 weeks before and 12 weeks after replacement of the conventional
treatment with PARI Master jet nebuliser by the PARI eFlow® rapid.
Lung function was prospectively assessed; inhalation time, medication and patients
comments on the new treatment option were assessed retrospectively by a standardised
interview.
Inhalation therapy was tobramycin in 50%, colistin in 18%, dornase alpha in 21% and
combination therapy in 11% of our patients, respectively. Reduction in treatment time
was comparable in all used inhaled medications.
Patients felt that the reduction of inhalation time was the main advantage of the new
nebuliser, whereas aspects like cleaning, integration of the nebuliser into physiotherapy
or tolerability of both nebulisers types were not signiﬁcantly different.
We conclude that the reduction in inhalation time about two-thirds with eFlow® rapid
was the most important advantage over Pari Master. Lung function parameters remained
stable during the study period.
Supported by: in part by PARI Inc., Starnberg, Germany
Comparison of lung function and inhalation time with PARI Master and 12 weeks after treatment
with PARI eFlow® rapid
n = 70 PARI Master PARI eFlow® rapid
mean FEV1 (SD, l) 2.41 (1.21) 2.40 (1.09)
mean MEF25 (SD, l/s) 0.54 (0.48) 0.63 (0.76)
mean daily inhalation time (SD, min) 27 (9) 9 (5)
168* Combined lung and liver transplantation in cystic ﬁbrosis
R. Souilamas1, G. Lenoir2, I. Sermet2, D. Dusser4, D. Hubert4, R. Guillemain1,
V. Boussaud1, R. Kanaan4, J. Fabiani1, O. Soubrane5. 1Transplantation, European
Georges Pompidou Hospital, Paris, France; 2Pediatric, Necker Hospital, Paris,
France; 3Pediatric Pneumology, Necker Hospital, Paris, France; 4Pneumology,
Cochin Hospital, Paris, France; 5General surgery, Cochin Hospital, Paris, France
Cystic ﬁbrosis patients with end-stage respiratory failure associated to liver cirrhosis
have been considered for lung transplantation. We report the experience of the
Georges Pompidou European Hospital and Cochin hospital in Paris.
Methods: Heart-lung-liver transplantation or sequential double lung-liver trans-
plantation were performed in 29 patients from 1990 to October 2005. We describe
surgical techniques and follow up, survival.
Results: Between June 1990 and October 2005, among 29 patients accepted in
the program for combined transplantation: heart-lung-liver transplantation (n = 5),
sequential double lung-liver transplantation (n = 24).
The age of the recipients ranged from 10 to 30 years. All patients had severe cirrho-
sis with portal hypertension. The operation was performed as a two-stage procedure,
the double lung transplantation being completed before the liver transplantation.
Post-operatives complications: 2 patients had liver primary graft dysfunction requir-
ing retransplantation, 2 patients had second laparotomy due to bleeding and another
due to liver abscess.
The post operative mortality was 24%. Actuarial survival was 70% at 1 year and
50% at 10 years. The incidence of BOS is 42% for 5 years with 25% of mortality.
Signiﬁcant functional improvement was observed in all survivors.
Conclusions: This report suggests that for these patients lung transplantation
combined with liver transplantation can be performed with the same outcome as
the double lung transplantation in cystic ﬁbrosis patients.
169 Risk factors for bronchiolitis obliterans syndrome (BOS) after
double lung transplantation for cystic ﬁbrosis (CF): 10-year
experience
S. Quattrucci, A.D. Grzejdziak, M. Rolla, S. Bertasi, D. Russo, L. Locorriere,
S. Benedetti Valentini, G. Cimino. Cystic Fibrosis Centre, Paediatrics, University
of Rome La Sapienza, Rome, Italy
BOS is the most frequent cause of death after lung transplantation (Ltx) and a
number of risk factors have been associated with this complication. We hereby
report our experience with 55 CF patients who underwent double Ltx over the last
10 years. BOS is deﬁned as a decrease of FEV1> 20% in the absence of other
detectable causes. Known risk factors for BOS are: multiple episodes of acute
rejection, human cytomegalovirus (HCMV) infection, bacterial or fungal infection,
gastroesophageal reﬂux, chronic renal failure.
From November 1996 to November 2006 we followed 55 (30 males) patients with
CF who underwent double Ltx. Of these, 28 (13 males) developed BOS and 13
died of this complication. Overall, BOS occurred at a mean time of 40 months
after Ltx, but the patients who died developed BOS earlier than those who are
currently alive. Death occurred after a mean time of 14 months after diagnosis
of BOS, whereas the patients who are alive have a mean FEV1 of 50% of the
predicted value and the mean time of follow-up of 95 months. Among possible
risk factors, we have identiﬁed chronic renal failure in 26 patients. The number
of acute rejections does not appear to be signiﬁcant, while the number of HCMV
infections reaches statistical signiﬁcance. It is remarkable the increase of fungal
infections starting 18 months after Ltx and its correlation with the occurrence of
BOS. In conclusion, early detection of BOS is vital for effective treatment. In our
experience the control of viral and fungal infections and the prevention of chronic
renal failure proved to be important factors for the prevention of BOS.
170 Following of lung transplantation for CF patients in Hungary
K. Kelemen1, K. Czebe1, B. Antus2, L. Kova´cs3, E. Csisze´r1. 1IVth Pulmonology,
National Koranyi Institute for TB and Pulmonology, Budapest, Hungary;
2Pathophysiology, National Koranyi Institute for TB and Pulmonology, Budapest,
Hungary; 3Ist Department of Pediatrics, Semmelweis University, Budapest,
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Lung transplantation is an accepted therapeutic modality for end-stage disease of the
lung associated with CF. For Hungarian patients the surgical process is available
at the Department of Cardiothoracic Surgery, University of Vienna, in a frame
of an international cooperation. Since 1996 were operated 20 CF-patients included
11 men and 9 women (mean age 22 years). One patient with mechanical ventilation
was put on the list and then operated. Survival time is 1−81mo (mean: 29mo). Two
patients died within 1 months after transplantion due infection.
During the post-operative care in Hungary one patient developed a severe Pseu-
domonas sepsis associated with endophthalmitis, mediastinitis, perinephric abscess
and septic pulmonary embolism. Later this patient developed an invasive pulmonary
Aspergillosis, as well. In one patient with acute abdominal syndrome we diagnosed
post-transplant lymphoproliferative disease (PTLD). Unfortunately, the patient de-
veloped later cerebral metastasis. One recipient should have been operated due to
distal intestinal obstruction syndrome (DIOS), and four due to sinonasal polyposis.
In one patient a granulomatous fungal skin infection was detected after an injury
in the knee.
CF recipients under the age of 18 years are treated in pediatric department, while
all others in adult pulmonary service. In three patients no clinical hospitalization
was necessary after transplantation. We aimed to keep a close collaboration with the
surgical team at the University of Vienna, and we believe that this also contributes
to the good long-term outcome observed in the majority of our lung transplant
patients with CF.
